Submucosal Tumor Removal by Endoscopic Excision Therapy
Key facts
- Who runs it
- Universitätsklinikum Hamburg-Eppendorf
- Where
- Germany3 sites in 1 countryChoose a country to see its locations
- Trial code
- Status
- Suspended
- People taking part
- 200 people, planned
- Started
- 10 Mar 2020
- Ended
- Feb 2025
- Type of study
- Interventional
- Treatments tested
- removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)
- Record updated
- 19 March 2024
- Why it stopped
- interim analysis
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Patients with endoscopically diagnosed and endosonographically confirmed submucosal tumors of 0.5 to 2 cm in the stomach without definitive histology / cytology
- Initial diagnosis less than 2 years ago
- No contraindication to endoscopic resection
- Patient's informed consent
Who cannot take part
- Tumors with proven / suspected malignancy for which oncologically no endoscopic resection should be performed, i.e. for which oncological or surgical therapy is planned
- Patients with severe general illnesses (limited operability) or malignancies
- Clotting disorders
- SMT known > 2 Years
- Tumor size > 2 cm
- Pregnancy
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
Smaller submucosal tumors (SMT) in the stomach are usually seen as an incidental finding during a gastroscopy, although current diagnostics usually do not clearly indicate what type of tumor it is. In summary, there is no good evidence for dealing with SMT. In this study, an endoscopic full-thickness resection, primarily with the FTRD device, is to be offered to all patients with gastric SMT without a confirmed histology seen in a certain period of time . Patients who do not want to take advantage of this are included in a systematic follow-up program.
Read full original descriptionShow less
The investigators hope to learn about the rate of so-called GIST tumors and other histologies, as well as the rate of change in the follow-up group.
Also, study contents will be accuracy of endosonographic imaging and puncture in comparison with resection histology, technical feasibility and histological completeness of the FTRD- based endoscopic (full-wall) resection option, complications of such a resection (secondary bleeding and dehiscences), and patient preferences with standardized information.
The group in the trial
- Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)Other group
FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective One-armed Observational Study of Full-thickness Resection of Small Hypoechoic Submucosal Gastric Tumors (≤2 cm)
- Record updated
- 19 March 2024